Where Will Minerva Neurosciences Inc (NERV) Stock Go Next After It Is Down 20.68% in a Week?

The market has been down on Minerva Neurosciences Inc (NERV) stock recently. NERV gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Minerva Neurosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NERV!

See Full NERV Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With NERV Stock Today?

Minerva Neurosciences Inc (NERV) stock is higher by 0.97% while the S&P 500 is down -0.41% as of 2:18 PM on Thursday, Jul 20. NERV has risen $0.09 from the previous closing price of $9.27 on volume of 92,872 shares. Over the past year the S&P 500 is up 15.50% while NERV has risen 227.27%. NERV lost -$5.49 per share in the over the last 12 months. To screen for more stocks like Minerva Neurosciences Inc click here.

More About Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease. Click Here to get the full Stock Report for Minerva Neurosciences Inc stock.